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Abstract
The much-publicised halting of the joint Merck/HIV Vaccine Trials Network phase IIB candidate
HIV-1 vaccine trial in 2007 has led to an unprecedented degree of discussion and introspection
amongst the HIV research community. In this commentary, we will summarise the lessons learned
from the trial and examine the current state of HIV vaccine research.
Introduction and context
The Merck/HIV Vaccine Trials Network (HVTN) 502
study, called STEP, started in late 2004 and was
terminated in September 2007. The phase IIB test-of-
concept, double-blinded, placebo-controlled trial was
conducted in North and South America, the Caribbean,
and Australia (areas where the predominant HIV-1
subtype is clade B). The aim of the STEP trial was to
generate a potent HIV-specific T-cell response, with the
hope of either conferring protection against infection or
decreasing ‘set-point’ plasma viraemia in subjects who
subsequently became infected with HIV-1, thus reducing
disease progression and potential viral transmission.
Almost 3,000 healthy uninfected young adult volunteers
considered to be at high risk of HIV-1 infection were
involved. Vaccinated subjects received three immunisa-
tions of three replication-defective adenoviral vectors
(rAd5), each carrying a gene encoding an HIV clade B
protein (Gag, Pol and Nef). At the time the trial was
started, this vaccine was the leading T-cell candidate and
had elicited the highest levels of T cell responses in phase
I studies [1]. As specified in the protocol, the trial data
were reviewed by the Data and Safety Monitoring Board
after 30 subjects had become infected. The trial was then
terminated because there was no apparent vaccine
efficacy, and - worryingly - a trend was noted for an
increased risk of infection in vaccinated subjects with
high titres of pre-existing neutralising antibodies (nAbs)
against adenovirus serotype 5 (Ad5), from which the
vector was derived [2,3]. Inevitably, halting the trial at
this stage meant that subsequent analysis was limited by
small numbers, a total of 49 infections in the vaccinated
group and 33 in the placebo group.
Overall, the STEP vaccine was as immunogenic as had
been predicted from earlier human studies, eliciting
significant interferon-gamma (IFN-g secretion in
response to two or three of the HIV proteins in most
subjects, detected by enzyme-linked immunosorbent
spot (ELISpot) assay, in 77% of vaccinees [3]. Moreover,
high frequencies of polyfunctional HIV-specific CD4
+
and CD8











of magnitude, breadth and functionality, the vaccine-
induced responses in those who became infected were
not significantly different from the responses in those
who remained uninfected [3]. However, despite the
encouraging early data in humans, the response to the
Ad5vectorhadbeen-withhindsight-lessencouragingin
studies conducted in non-human primates [4]. Although
there had been evidence of a reduction in viral load of
1 to 3 logs in vaccinated macaques following challenge
with SHIV [a chimaeric virus expressing HIV internal
genes and simian immunodeficiency virus (SIV) envel-
ope] [5], a more stringent challenge with the more
virulent SIV strain, SIVmac239, led to just a modest
(1 log) decrease of viral load, which was seen only in
Page 1 of 5
(page number not for citation purposes)
Published: 29 June 2009
© 2009 Biology Reports Ltd
)
for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,monkeys carrying the protective major histocompatibil-
ity complex class I allele Mamu-A*01 [6]. It has been
argued that more attention needs to be paid to the
outcome of appropriate macaque challenge models in
selecting the vaccine candidates that go through to large
clinical trials in humans [7].
Although the numbers of new HIV-1 infections in the
STEP trial were too small to demonstrate unequivocally
that pre-existing Ad5 immunity actually increased
susceptibility to infection, there was a trend toward a
higher infection rate in subjects with high titres of Ad5-
specific nAbs, particularly in uncircumcised men, how-
ever, the data could also be interpreted - somewhat
paradoxically - as showing a lower rate of infection in
placebo recipients with high Ad5 antibody titres [8]. If
pre-existing Ad5 immunity really does increase HIV-1
susceptibility, one possible mechanism would be a
vaccine-mediated increase in immune activation leading
to a larger pool of activated HIV-susceptible T cells. In
order to address this question, cellular immune activa-
tion and expression of HIV-1 co-receptors were studied
in infected and uninfected vaccine recipients with
different levels of Ad5 antibodies. Activation levels
were in fact higher in those with higher antibody titres,
but only in placebo recipients and in vaccine recipients
who did not become infected, suggesting that cellular
activation did not play a major part in increasing
susceptibility in those with prior Ad5 immunity. Never-
theless, in vitro studies have shown that Ad5-antibody
immune complexes can promote HIV-1 infection by
inducing dendritic cell maturation and enhancing HIV-1
transmission to T cells [9]. Moreover, prior adenoviral
immunity impinged on vaccine immunogenicity: fre-
quencies of HIV-specific CD8
+ T cells were significantly
lower in subjects with pre-existing Ad5 nAbs compared
with naïve subjects [3]. However, examination of further
data from the STEP trial, looking at participants who,
despite extensive counselling, became infected after the
trial was terminated, shows that the effect of pre-existing
adenovirus immunity no longer has an impact on the
likelihood of infection in vaccines (Julie McElrath,
presentation at the Keystone meeting on HIV prevention,
March 2009).
Major recent advances
Does the setback of the STEP study imply that the general
concept of T cell-based vaccine is flawed or is this simply
a failure of a particular product? Could other T cell
vaccination regimens using different vectors fare better?
Recently, Liu and colleagues [10] succeeded in eliciting a
protective T-cell response against SIV using an immuni-
sation strategy similar to that of the STEP study, but
using two different adenovirus vectors. Significant
protection of rhesus monkeys from challenge with
SIVmac251 was afforded following immunisation with
an rAd26-Gag prime/rAd5-Gag boost regimen. This
heterologous prime-boost strategy elicited a Gag-specific
T-cell response of higher magnitude, breath and poly-
functionality than the rAd5-Gag prime/rAd5-Gag strat-
egy used in the STEP study, and this correlated with
control of set-point viral loads. HIV-specific T cells were
primarily IL-2
+ (as opposed to IFN-g
+ generated with the
rAd5-Gag prime/rAd5-Gag regimen and the STEP study),
and gastrointestinal CD4
+ T cells and peripheral CCR5
+
central memory CD4
+ T cells were preserved. These
results strongly suggest that the use of vectors other than
the Ad5 vector used during the STEP trial should be
considered and provide encouragement that a setback of
the STEP trial does not imply a failure of the overall
T cell-based vaccine concept. Following a period of
considerable introspection after the STEP trial, HIV
vaccine researchers have identified some critical con-
siderations to be addressed before embarking upon
further large-scale clinical vaccine studies.
Achieving a better fundamental understanding of the
pathogenesis and immune response to HIV-1 infection
The critical featuresof protective immunity against HIV-1
infection remain poorly understood because, in contrast
to most infections for which we have effective preventa-
tive vaccine, there are no records of any individuals
having completely eliminated the virus. Continued
studies of people with a good outcome of their
encounter with HIV-1 infection (HEPS [highly exposed
persistently seronegative] subjects and those with long-
term viral control, not only with HIV-1 but also with
HIV-2 infection [11]), as well as new and improved
animal models, are needed to determine the correlates of
protective immunity.
Improving the definition of the correlates of
T cell-mediated protection during HIV infection
and following vaccination
It has been well established that neither the magnitude
nor the breadth of the HIV-specific IFN-g response
measured by ELISpot assays correlates with any clinical
parameter in infected patients [12], strongly implying
that there are better functional correlates of an effective
antiviral T-cell response. Migueles and colleagues [13]
recently developed an assay that detects the delivery of
functional Granzyme B into HIV-infected cells. Lytic
granule loading of effectors and delivery to target cells
are critical determinants of cytotoxicity and immunolo-
gic control. Assuming that diminished killing capacity
of HIV-specific cytotoxic CD8
+ T cells is due to deficient
loading of lytic granules into targets, such an assay
should be considered in the testing of new vaccines.
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+) correlates with delayed disease
progression [14], the concept of polyfunctionality
should be more clearly defined: could other even more
critical soluble factors or effector functions be identified?
Furthermore, the field needs to develop assays to
measure renewal and persistence of the memory T-cell
response. Hansen and colleagues [15] have shown that
SIV-infected rhesus macaques vaccinated with a RhCMV
(rhesus cytomegalovirus) vector expressing SIV Gag,
Rev-Tat-Nef and Env developed robust and sustainable
CD4
+ and CD8
+ T-cell responses that were sufficient to
mediate protection against infection with the highly
pathogenic strain, SIVmac239, after repeated mucosal
challenges. Protection was associated with effector
memory T (TEM) cells producing TNF-a, IFN-g and
MIP-1b (macrophage inflammatory protein-1-beta) in
the absence of nAbs [15]. This implies that TEM cells may
have the ability to prevent sexual transmission of HIV,
hence correlates of functional memory need to be easily
identifiable. Progressive impairment of T cell fitness
during chronic infection is also an important parameter.
T cell exhaustion and senescence correlate with an
increase in viral load [16], whilst preservation of
proliferative capacity is associated with viral control
[17,18]. The ability of T cells to suppress virus in vitro
may be a better indication of their antiviral potency and
does not always correlate with other assays of T cell
function [19]; it would be valuable to develop similar
suppression assays that could be scaled up in vaccine
studies. Lastly, although blood remains the most
accessible tissue, recent appreciation that crucial immu-
nopathological events occur in mucosal compartments
early after infection [20,21] suggests that sampling these
sites may provide more relevant data about pathogenesis
and protective immunity. Studies of non-human pri-
mates infected with SIV would be useful in determining
whether this approach is feasible.
A better characterisation of the innate response to HIV-1
would influence the quality and magnitude of
the adaptive immune response
The strong relationship between KIR (killer immunoglo-
bulin-like receptor) genotypes and HIV-1 disease out-
come [22,23] strongly suggests that natural killer (NK)
cell responses are likely to play an important role at early
stages of infection and thus be decisive for the outcome
of disease, but correlates of an effective innate immune
response are still ill defined and it is not yet clear how
this may be influenced by vaccine strategies [24].
Selecting alternative vaccine vectors
Other vectors, such as other adenoviral vectors that rarely
cause infection in humans (for example, simian and
ovine adenoviruses), and poxviruses, merit further study.
The impact of pre-existing immunity as well as the
immune response to these vectors should be charac-
terised in detail. Poxvectors are a particularly promising
option since most individuals born after 1974 have not
been in contact with the virus, thus preventing the
scenario that appeared to be an issue during the STEP
study. It is also important to consider that similar vectors
are being developed for other novel vaccines, such as for
tuberculosis and malaria, so consideration should be
given to how these vaccines can be effectively used
together.
Determining whether a broadly neutralising antibody
response against HIV-1 infection is achievable
Given that most of the successful licensed vaccines rely
on the generation of virus-specific nAbs and that
administration of high doses of broadly neutralising
monoclonal antibodies provides sterilising immunity to
HIV [25], it has become imperative to determine how
this could be achieved in the context of HIV infection.
Masking of epitopes by glycosylation and the high
mutation rate of the viral envelope are two main reasons
why nAbs against HIV are difficult to induce [26].
However, other antibody-mediated antiviral activities
such as antibody-dependent cell-mediated cytotoxicity
in October 2003, involved more than 16,000 healthy
uninfected volunteers and will be completed by June
2009. The vaccination strategy was as follows: (a) at
weeks 0, 4, 12 and 24, subjects were primed with
ALVAC-HIV (vCP1521), a recombinant canarypox vector
expressing subtype E HIV-1 gp120 linked to a transmem-
brane anchoring portion of gp41, and HIV-1 Gag and
protease, and (b) at weeks 12 and 24, subjects were given
a bivalent AIDSVAX B/E gp120 boost [27]. Preliminary
results showed that the vaccine induced a potent ADCC
significantly different from that of placebo recipients. In
previous phase I/II testing, this regimen induced higher
binding and nAb titres and a lymphoproliferative
response in vaccine recipients compared with the
placebo group. Whether this prime-boost vaccine com-
bination can afford protection against HIV is not yet
known, but the presence of gp120 ADCC antibodies
following vaccination is encouraging.
Learning from other successful anti-viral vaccines
Inspiration for the HIV vaccine endeavour has been
sought from other vaccines that have been successful at
eliciting protective immunity [28,29]. Recently, micro-
array transcriptional profiling and multiplex cytokine
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(ADCC) may be equally valuable. The phase III trialof
Thailand is promising in this regard. This study started
gp120 B/E (AIDSVAX B/E) prime-boost vaccine in
the Aventis Pasteur ALVAC-HIV (vCP1521)/VaxGenanalysis revealed that activation of master-switch genes
following yellow fever vaccination induces several path-
ways of innate and adaptive immune response,including
complement, Th1/Th2 polarisation and B cells [30]. This
approach permitted the identification of a distinct
signature of gene activation and accurately predicted
CD8
+ T-cell and B-cell responses. Thus, new technologies
and system biology approaches should be included in
future studies in order to decipher the intricacy of HIV
and to assist the design of future effective vaccines.
Future directions
In summary, the next generation of HIV vaccines will
probably need to elicit broader and more polyfunctional,
potent, and persistent T-cell responses than those
achieved in the STEP study and then may provide partial
protection against HIV-1 infection. T cell immunity
could be enhanced by mobilising innate immunity (NK
cells in particular), whilst the generation of a broadly
nAb response remains elusive. Huge challenges never-
theless will remain to generate vaccines that can
effectively protect against the multiplicity of HIV-1
variants that have emerged worldwide in the past few
decades and to combat the ability of this virus to create
latent lifelong reservoirs.
Abbreviations
Ad5, adenovirus serotype 5; ADCC, antibody-dependent
cell-mediated cytotoxicity;E L I S p o t ,e n z y m e - l i n k e d
immunosorbent spot; HEPS, highly exposed persistently
seronegative; HVTN, HIV Vaccine Trials Network; IFN-g,
interferon-gamma; IL-2, interleukin-2; KIR, killer immu-
noglobulin-like receptor; MIP-1b, macrophage inflam-
matory protein-1-beta; nAb, neutralising antibody; NK,
natural killer; rAd5, replication-defective adenovirus
serotype 5; RhCMV, rhesus cytomegalovirus; SIV, simian
immunodeficiency virus; TEM, effector memory T; TNF-a,
tumour necrosis factor-alpha.
Competing interests
The authors declare that they have no competing
interests.
References
1. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J,
Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P,
Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ,
Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E: Safety
and immunogenicity of a replication-incompetent adenovirus
type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin
Infect Dis 2008, 46:1769-81.
2. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D,
Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ,
Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L,
Robertson MN: Efficacy assessment of a cell-mediated immu-
nity HIV-1 vaccine (the Step Study): a double-blind,
randomised, placebo-controlled, test-of-concept trial. Lancet
2008, 372:1881-93.
3. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H,
Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP,
Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW,
Casimiro DR: HIV-1 vaccine-induced immunity in the test-of-
concept Step Study: a case-cohort analysis. Lancet 2008,
372:1894-905.
F1000 Factor 3.0 Recommended
Evaluated by Sarah Rowland-Jones 09 Dec 2008
4. Sekaly RP: The failed HIV Merck vaccine study: a step back or a
launching point for future vaccine development? J Exp Med
2008, 205:7-12.
5. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK,
Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA,
Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV,
Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB,
Replication-incompetent adenoviral vaccine vector elicits
effective anti-immunodeficiency-virus immunity. Nature 2002,
415:331-5.
F1000 Factor 6.0 Must Read
Evaluated by Bernard Moss 04 Feb 2002
6. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW,
Davies ME, McDermott AB, O’Connor DH, Fridman A, Bagchi A,
Tussey LG, Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA,
Chen M, Perry HC, Heidecker GJ, Freed DC, Carella A, Punt KS,
Sykes KJ, Huang L, Ausensi VI, Bachinsky M, Sadasivan-Nair U,
Attenuation of simian immunode-
ficiency virus SIVmac239 infection by prophylactic immuni-
zation with dna and recombinant adenoviral vaccine vectors
expressing Gag. J Virol 2005, 79:15547-55.
7. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC: Nonhuman
primate models and the failure of the Merck HIV-1 vaccine in
humans. Nat Med 2008, 14:617-21.
8. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK: AIDS/HIV. A STEP into
darkness or light? Science 2008, 320:753-5.
9. Perreau M, Pantaleo G, Kremer EJ: Activation of a dendritic cell-T
cell axis by Ad5 immune complexes creates an improved
environment for replication of HIV in T cells. J Exp Med 2008,
205:2717-25.
F1000 Factor 3.0 Recommended
Evaluated by Lindsey Hutt-Fletcher 06 Nov 2008
10. Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM,
Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G,
Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ,
Pau MG, Goudsmit J, Barouch DH: Immune control of an SIV
challenge by a T-cell-based vaccine in rhesus monkeys. Nature
2009, 457:87-91.
F1000 Factor 9.0 Exceptional
Evaluated by Alan Landay 06 Feb 2009
11. Rowland-Jones SL, Whittle HC: Out of Africa: what can we learn
from HIV-2 about protective immunity to HIV-1? Nat Immunol
2007, 8:329-31.
12. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D,
Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME,
Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C,
Goulder PJ, Rosenberg ES, Altfeld M, Walker BD: Comprehensive
epitope analysis of human immunodeficiency virus type 1
(HIV-1)-specific T-cell responses directed against the entire
expressed HIV-1 genome demonstrate broadly directed
responses, but no correlation to viral load. J Virol 2003,
77:2081-92.
13. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP,
Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA,
Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C,
O’Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP,
Page 4 of 5
(page number not for citation purposes)
F1000 Biology Reports 2009, 1:50 http://F1000.com/Reports/Biology/content/1/50
Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM et al. :
Watkins DI, Emini EA .:
.
et al.Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA,
Connors M: Lytic granule loading of CD8+ T cells is required
for HIV-infected cell elimination associated with immune
control. Immunity 2008, 29:1009-21.
F1000 Factor 8.0 Exceptional
Evaluated by Holden Maecker 20 Feb 2009, Sheena McCormack 26
May 2009
14. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J,
Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M,
Koup RA: HIV nonprogressors preferentially maintain highly
functional HIV-specific CD8
+ T cells. Blood 2006, 107:4781-9.
15. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC,
Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM,
Piatak M Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ: Effector
memory T cell responses are associated with protection of
rhesus monkeys from mucosal simian immunodeficiency
virus challenge. Nat Med 2009, 15:293-9.
F1000 Factor 4.8 Must Read
Evaluated by Lindsey Hutt-Fletcher 01 Apr 2009, Sarah Rowland-
Jones 02 Jun 2009
16. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S,
Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z,
Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ,
Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ,
Walker BD: PD-1 expression on HIV-specific T cells is
associated with T-cell exhaustion and disease progression.
Nature 2006, 443:350-4.
F1000 Factor 6.5 Must Read
Evaluated by Steve Ward 30 Aug 2006, Sarah Rowland-Jones 11 Sep
2006, Luis J Montaner 14 Dec 2006
17. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E,
Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D,
Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V:
Superior control of HIV-1 replication by CD8
+ T cells is
reflected by their avidity, polyfunctionality, and clonal turn-
over. J Exp Med 2007, 204:2473-85.
F1000 Factor 3.0 Recommended
Evaluated by Sarah Rowland-Jones 23 Oct 2007
18. Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N,
Honeyborne I, Crawford H, Coovadia HM, Goulder PJ, Walker BD,
Klenerman P: Proliferative capacity of epitope-specific CD8
T-cell responses is inversely related to viral load in chronic
human immunodeficiency virus type 1 infection. J Virol 2007,
81:434-8.
19. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD,
Baker BM, Rothchild AC, Block BL, Schneidewind A, Koibuchi T,
Pereyra F, Allen TM, Walker BD: Differential neutralization of
human immunodeficiency virus (HIV) replication in auto-
logous CD4 T cells by HIV-specific cytotoxic T lymphocytes.
J Virol 2009, 83:3138-49.
F1000 Factor 3.0 Recommended
Evaluated by Paul Goepfert 09 Apr 2009
20. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M:
Massive infection and loss of memory CD4
+ T cells in
multiple tissues during acute SIV infection. Nature 2005,
434:1093-7.
F1000 Factor 8.4 Exceptional
Evaluated by Rino Rappuoli 17 May 2005, James Crowe 19 May
2005, Luis J Montaner 19 May 2005, Sarah Rowland-Jones 19 May
2005
21. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ,
Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR,
Pambuccian S, Lifson JD, Carlis JV, Haase AT: Glycerol
monolaurate prevents mucosal SIV transmission. Nature
2009, 458:1034-8.
F1000 Factor 9.6 Exceptional
Evaluated by Sarah Rowland-Jones 19 Mar 2009, Gene Shearer 01
Apr 2009
22. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ,
Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O’Brien SJ,
CarringtonM:EpistaticinteractionbetweenKIR3DS1andHLA-
B delays the progression to AIDS. Nat Genet 2002, 31:429-34.
F1000 Factor 6.7 Must Read
Evaluated by Sarah Rowland-Jones 01 Aug 2002, Terri Beaty 09 Aug
2002, Lutz Walter 03 Sep 2002, Eric Long 04 Dec 2002
23. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S,
Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD,
Telenti A, Connors M, O’Brien SJ, Walker BD, Parham P, Deeks SG,
McVicar DW, Carrington M: Innate partnership of HLA-B and
KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733-40.
F1000 Factor 4.8 Must Read
Evaluated by Lutz Walter 20 Jun 2007, Luis J Montaner 04 Sep 2007
24. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ,
Schneidewind A, Streeck H, Waring M, Meier A, Brander C,
Lifson JD, Allen TM, Carrington M, Altfeld M: Differential natural
killer cell-mediated inhibition of HIV-1 replication based on
distinct KIR/HLA subtypes. J Exp Med 2007, 204:3027-36.
25. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S,
Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA,
Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC,
Ruprecht RM: Human neutralizing monoclonal antibodies of
the IgG1 subtype protect against mucosal simian-human
immunodeficiency virus infection. Nat Med 2000, 6:200-6.
26. BurtonDR,DesrosiersRC,DomsRW,KoffWC,KwongPD,MooreJP,
Nabel GJ, Sodroski J, Wilson IA, Wyatt RT: HIV vaccine design and
the neutralizing antibody problem. Nat Immunol 2004, 5:233-6.
27. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M,
Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim S, Kim J,
Thapinta D, Garner R, Bussaratid V, Singharaj P, el-Habib R,
Gurunathan S, Heyward W, Birx D, McNeil J, Brown AE: Safety
and immunogenicity of an HIV subtype B and E prime-boost
vaccine combination in HIV-negative Thai adults. J Infect Dis
2004, 190:702-6.
28. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-
Mouhim A, Moser JM, Mehta RS, Drake DR 3rd, Castro E, Akondy R,
Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R,
Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P,
Pantaleo G, Tartaglia J, Haddad EK, Sekaly RP: Yellow fever vaccine
induces integrated multilineage and polyfunctional immune
responses. J Exp Med 2008, 205:3119-31.
F1000 Factor 6.0 Must Read
Evaluated by Jason Brenchley 16 Dec 2008
29. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S,
Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S,
Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD,
Feinberg MB, Ahmed R: Human effector and memory CD8
+
T cell responses to smallpox and yellow fever vaccines.
Immunity 2008, 28:710-22.
F1000 Factor 8.2 Exceptional
Evaluated by Ann Duerr 02 Jun 2008, Paul Goepfert 03 Jun 2008,
Holden Maecker 17 Jun 2008
30. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D,
Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H,
Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A,
Ahmed R, Pulendran B: Systems biology approach predicts
immunogenicity of the yellow fever vaccine in humans. Nat
Immunol 2009, 10:116-25.
F1000 Factor 6.0 Must Read
Evaluated by Barry Rouse 25 Nov 2008
Page 5 of 5
(page number not for citation purposes)
F1000 Biology Reports 2009, 1:50 http://F1000.com/Reports/Biology/content/1/50